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Abstract
Latent Epstein-Barr virus (EBV) has been shown to protect Burkitt’s lymphoma-derived B cells from apoptosis induced by
agents that cause damage to DNA, in the context of mutant p53. This protection requires expression of the latency-
associated nuclear proteins EBNA3A and EBNA3C and correlates with their ability to cooperate in the repression of the gene
encoding the pro-apoptotic, BH3-only protein BIM. Here we confirm that latent EBV in B cells also inhibits apoptosis induced
by two other agents – ionomycin and staurosporine – and show that these act by a distinct pathway that involves a p53-
independent increase in expression of another pro-apoptotic, BH3-only protein, NOXA. Analyses employing a variety of B
cells infected with naturally occurring EBV or B95.8 EBV-BAC recombinant mutants indicated that the block to NOXA
induction does not depend on the well-characterized viral latency-associated genes (EBNAs 1, 2, 3A, 3B, 3C, the LMPs or the
EBERs) or expression of BIM. Regulation of NOXA was shown to be at least partly at the level of mRNA and the requirement
for NOXA to induce cell death in this context was demonstrated by NOXA-specific shRNA-mediated depletion experiments.
Although recombinant EBV with a deletion removing the BHRF1 locus – that encodes the BCL2-homologue BHRF1 and three
microRNAs – partially abrogates protection against ionomycin and staurosporine, the deletion has no effect on the EBV-
mediated block to NOXA accumulation.
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Introduction
In vitro, EBV can very efficiently induce the activation and
continuous proliferation of primary human B cells. The resulting
‘immortalized’ lymphoblastoid cell lines (LCLs) carry the viral
genome as extra-chromosomal episomes and express only nine
latency-associated EBV proteins. There are six nuclear antigens
(EBNAs 1, 2, 3A, 3B, 3C & -LP), three membrane associated
proteins (LMP1, LMP2A & 2B) and several untranslated RNA
species (EBERs and BARTs). This programme of viral gene
expression is known as latency III or the ‘growth programme’
[1,2,3].
However, data on the persistence of EBV in humans are
consistent with the viral genome residing long-term in a resting
memory B cell population in which no EBV proteins are
expressed. It is now considered probable that to establish
persistence, EBV initially infects resting (naı ¨ve) B cells and drives
these to proliferate as activated B-blasts. This expanding infected
B-blast population then migrates into germinal centres, where the
infected cells differentiate to become centroblasts, centrocytes and
finally resting memory B cells. While the precise series of events
that the EBV-positive B cells undergo to reach the memory
compartment is unknown, it appears to involve regulated shut-
down of latency-associated viral gene expression from an initial
state (latency III, as found in LCLs) in B-blasts, via latency II
(EBNA1, the LMPs, the EBERs and BARTs) in centroblasts and
centroctyes until in quiescent memory B cells no EBV protein
transcripts can be detected in a state called latency 0. When resting
memory cells re-enter the cell cycle and divide, EBNA1 alone
becomes detectable (termed latency I) [3,4,5].
Although persistent infection is normally asymptomatic, EBV
can be the causative agent in the benign lymphoproliferation
known as infectious mononucleosis, and the virus is also
etiologically linked to a number of human cancers including
Burkitt’s lymphoma (BL), Hodgkin’s lymphoma, diffuse large B
cell lymphoma, and epithelial-derived nasopharyngeal carcinoma
[1,6]. In normal individuals the accumulation of proliferating B
cells is counterbalanced by differentiation into memory and also
the action of EBV-specific cytotoxic T lymphocytes that recognise
and destroy the proliferating B-blasts [7].
There is a great deal of evidence that EBV gene expression can
very effectively suppress the process of programmed cell suicide
known as apoptosis [8,9,10,11,12,13,14,15,16]. This ability of a
virus to regulate apoptosis is generally considered to be important
because apoptosis is a major antiviral response used by
multicellular organisms for the removal of infected cells. EBV
has therefore evolved multiple mechanisms to ensure the survival
of infected cells long enough for the virus to establish persistent
latent infection and subsequently undergo ‘lytic’ replication to
produce new infectious virus. Furthermore, B cells – the primary
target for EBV infection – are particularly prone to apoptosis
when they pass through germinal centres because this is where
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antigen are removed. During B cell development, therefore,
multiple regulators of apoptosis act to cull B cells at different stages
in order to maintain homeostasis of the B cell compartment [17].
Inhibition of apoptosis by EBV is also generally considered to
make a major contribution to the malignant transformation of
infected cells, and hence the development of EBV-associated
cancers – reviewed in [18,19].
Numerous studies of EBV and apoptosis have identified most of
the viral latency-associated gene products as having some anti-
apoptotic activity (reviewed in [18,19]), and a great deal of effort
has gone into showing that the presence of latent EBV in BL-
derived cells rescues them from apoptosis triggered by a wide
range of exogenous stimuli – including cytotoxic drugs, cytokine
deprivation, anti-IgM andc-irradiation [13,20,21,22]. This means
comparison between studies is often difficult. For instance, we
recently showed that the EBV-mediated protection against
apoptosis specifically induced by either the DNA cross-linking
agent cisplatin, the cyclin-dependent kinase inhibitor roscovitine
or the mitotic spindle poison nocodazole is dependent on the co-
expression of EBV latency-associated proteins EBNA3A and
EBNA3C [21,22]. This correlates with the down-regulation of the
pro-apoptotic BH3-only protein BIM, which depends on expres-
sion of both EBNA3A and EBNA3C. This protection is
independent of the tumour suppressor p53, which is often mutated
in BL cells, including BL31 used in the study. However, we noted
that when similar experiments were repeated using BL2 cells and
their EBV-infected counterparts, both of which carry wild type
p53 but fail to express BIM, latent EBV was unable to protect
against apoptosis induced by the same agents [22]. This is because
these genotoxic agents induce the stabilization and activation of
the wild type p53 present in BL2 and the activation of an apoptotic
pathway that is independent of BIM. Consistent with this, EBV
does not block p53-induced apoptosis after DNA-damage to LCLs
[23,24].
In contrast with these observations, Kelly and colleagues found
that latent EBV protects both BL31 cells (BIM-positive and
carrying a mutant p53) and BL2 cells (BIM-negative and carrying
wild type p53) equally well against apoptosis induced by the
calcium-ionophore ionomycin and that the EBNA3 proteins
appeared to play no role in this [20,25]. We hypothesised that
this must depend on a second pathway by which BL cells can be
triggered to undergo apoptosis, that this is independent of EBNA3-
, BIM- and p53-status, but can also be blocked very effectively by
EBV. Here we have explored this alternative pathway and
established that it involves the p53-independent accumulation of
another pro-apoptotic, BH3-only protein, NOXA. The mecha-
nism by which EBV protects the cells from this agent does not
involve any of the well-characterised latency factors (including
EBNA3A and EBNA3C), but is partly dependent on products of
the EBV BHRF1 locus – apparently acting alongside, but
independently of NOXA.
Results
Confirmation that EBV latency-associated gene
expression confers resistance against ionomycin-induced
apoptosis
EBV-negative BL41 and two EBV-positive BL41 cell lines
converted by infection using different virus strains, B95.8 and
P3HR1, were treated with ionomycin at a concentration of 1 mg/
ml for 48 hours (Figure 1A). BL41 is null for (WT) p53 because it
carries only a single, mutant allele [26]. After treatment for
48 hours, fewer than 20% of BL41 cells remain viable. In contrast,
BL41/B95.8 cells, which display the latency III phenotype, appear
to be completely resistant to ionomycin-induced apoptosis and
continue to proliferate. A similar response was observed in BL41/
P3HR1 cells, which express a restricted set of latent proteins, as a
result of a deletion in the region encoding EBNA2 and the two
unique C-terminal exons of EBNA-LP (reviewed in [27]). As a
result BL41/P3HR1 cells only express the latent proteins EBNA1,
EBNA3A, EBNA3B, EBNA3C, a truncated form of EBNA-LP,
and the EBERs and BARTs; the LMPs are not expressed because
generally EBNA2 is required to transactivate their expression.
Similarly, the responses of more recently described BL lines,
Oku-BL and Sal-BL, were also analysed (Figure 1A). These early
passage cell lines were established from BL biopsy material [28]
and found to carry EBV genomes with EBNA2 deletions similar to
that of the P3HR1 strain. These cell lines are termed ‘Wp-
restricted’ because the EBNA2 deletion causes the Wp promoter,
rather than Cp, to remain the main originator of EBNA
transcripts. Oku-BL and Sal-BL therefore express the same subset
of EBV genes as BL41/P3HR1. However unlike BL41, both Oku-
BL and Sal-BL carry wild-type (WT) p53 [22]. The data confirm
that the ionomycin-resistant phenotype is not specific to BL41 and
suggest that the restricted set of EBV proteins associated with the
P3HR1 strain is sufficient to protect BL cells from ionomycin-
induced apoptosis irrespective of the p53-status of cells.
BL2 cells – which have WT p53, but fail to express the pro-
apoptotic factor BIM [22] – were infected with a recombinant
EBV-BAC from which the EBNA2 open reading frame (ORF) had
been deleted to produce a P3HR1-like virus (E2KO), but carrying
a full length EBNA-LP [20]. As seen with EBV-negative BL41,
BL2 cells were susceptible to ionomycin-induced apoptosis, as
measured by viability. In contrast, BL2 cells latently infected with
recombinant E2KO virus were protected from ionomycin-induced
apoptosis (Figure 1B). These results confirm that the limited
pattern of EBV gene expression associated with P3HR1, Oku-BL,
Sal-BL and an E2KO virus is sufficient to enhance survival of
ionomycin treated cells, that BIM is not involved in this pathway
to apoptosis and that the p53 context is unimportant. Throughout,
in order to confirm that death was a result of cells undergoing
apoptosis, protein extracts prepared from treated and untreated
cells were separated by SDS-PAGE and analysed by western
blotting using an antibody which detects both full length
poly(ADP-ribose) polymerase (PARP) and its cleaved fragments.
PARP is proteolytically cleaved from a full-length 113 kDa protein
to 89 kDa and 24 kDa fragments by caspases activated during
apoptosis. PARP cleavage is widely accepted to be a hallmark of
programmed cell death [29]. All these data are shown in
supplementary Figure S1.
Having confirmed that the EBV-mediated protection of BL cells
from ionomycin-induced apoptosis only requires the expression of
a limited set of viral genes, the number of candidate genes was
reduced further by assessing the response of cells that exhibit type I
latency. This is a restricted form of EBV latency in which only
EBNA1, the EBERs and BARTs are expressed, and is the EBV
gene expression pattern found in the majority of primary EBV-
positive BL. The Latency I BL-derived line, Mutu I, was used for
investigation. Mutu cells that had drifted in culture to produce the
full latency III pattern of EBV gene expression (Mutu III) were
analysed for comparison. Figures 1C and S1 show that Mutu III
cells were resistant to ionomycin-induced apoptosis and continued
to proliferate. In contrast, fewer than 20% of Mutu I cells survived
after 48 hours of exposure to ionomycin and complete cleavage of
full-length PARP was observed, consistent with death by apoptosis
in response to ionomycin. These data demonstrate that type I
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ionomycin-induced apoptosis.
Since the experiments described so far utilized BL-derived cells,
we determined whether two lymphoblastoid cell lines, LCL-BF
and LCL-CH, established by infection of primary B cells with the
B95-8 strain of EBV [30] show the same resistance to ionomycin
as type III BL cells. Viable cell counts for both these LCLs showed
that at least 90% of cells survived after 48 hours of exposure to
ionomycin (Figure 1D). PARP is also unaltered by treatment in
both LCLs, confirming that these LCLs failed to undergo
apoptosis even after exposure to ionomycin for 48 hours (Figure
S1). These results are in marked contrast to the response of LCLs
to genotoxic drugs such as cisplatin and nocodazole, since EBV
cannot protect against genotoxin-induced, p53-mediated apoptosis
in LCLs [23].
EBNA3A, EBNA3B and EBNA3C are not involved in
protection against ionomycin-induced apoptosis
Expression of both EBNA3A and EBNA3C is necessary to
inhibit genotoxin-induced apoptosis in a p53-mutant background
[21,22], we therefore asked whether expression of EBNA3A,
EBNA3B and EBNA3C is necessary for resistance to ionomycin in
Figure 1. Latent EBV inhibits ionomycin-induced apoptosis in a variety of cell backgrounds. (A) BL41 and its EBV-positive counterparts,
BL41/B95.8 and BL41/P3HR1, and two Wp-restricted BL Oku-BL and Sal-BL, (B) BL2 and its EBV-positive convert established with a recombinant
EBNA2-knockout virus (BL2+E2KO), (C) Mutu III (expressing all the latency-associated proteins) and Mutu I (expressing only EBNA1) and (D) two LCLs
were all treated with 1 mg/ml ionomycin (IM) for up to 48 hours. Viable cells (assessed by trypan blue exclusion) were counted. Cell survival is
expressed as a percentage relative to the starting population and the mean and standard deviation of viable cell counts from three independent
experiments are shown.
doi:10.1371/journal.pone.0028506.g001
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BL31 cells, along with BL31 cells infected with BAC-derived
EBNA3A, EBNA3B or EBNA3C knockout viruses (3AKO, 3BKO
and 3CKO respectively), their revertants (3Arev, 3Brev and 3Crev
respectively) or wild type (WT, derived from the prototype B95.8
strain) viruses (described in [22]) were treated with ionomycin.
After 48 hours, more than 80% of the parental EBV-negative
BL31 cells were dead (Figure 2A) and exhibited considerable
cleavage of PARP (Figure S2). As expected, infection of BL31 cells
with WT EBV or any of the revertant viruses improved survival
dramatically. Interestingly – as predicted by Kelly et al [25] – BL31
cells infected with the 3AKO, 3BKO or 3CKO viruses were also
resistant to ionomycin-induced apoptosis, with at least 90% of cells
remaining viable after 48 hours. This survival was also reflected by
absence of PARP cleavage in these cell lines (Figure S2). This
demonstrates that in BL31 cells the absence of EBNA3A,
EBNA3B or EBNA3C individually has little or no effect on the
EBV-mediated protection against ionomycin-induced apoptosis
and is in marked contrast to the contribution both EBNA3A and
EBNA3C make to the EBV-mediated protection of similar BL
cells against apoptosis induced by genotoxic drugs such as cisplatin
[22]. In order to show that these observations were not specific to
BL31 cells, experiments were repeated using a panel of BL2 cells
(which lack BIM, but carry WT p53) infected with recombinant
3AKO, 3BKO, 3CKO, revertant or WT EBV. The results
obtained from the BL2 panel of cells are similar to those obtained
with the BL31 panel (data not shown). Together these results
indicate that individually deleting EBNAs 3A, 3B or 3C does not
alter the protection conferred by EBV against ionomycin-induced
apoptosis. The data also confirm the observations that the
apoptotic pathway induced by ionomycin is independent of both
p53 and BIM.
While removing EBNA3A, EBNA3B or EBNA3C individually
did not alter the capacity of EBV to protect against ionomycin, the
possibility of functional redundancy between the EBNA3 proteins
could not be ruled out. Therefore, a recombinant EBV harbouring
a deletion of the entire EBNA3 locus (E3KO) was constructed and
BL31 and BL2 cells were established by infection with E3KO or its
revertant (E3rev) [31]. While few of the parental BL31 cells
remain viable after 48 hours of exposure to ionomycin, BL31 cells
infected with the E3KO, WT and revertant viruses are all resistant
to ionomycin-induced apoptosis, as measured by viability and
PARP cleavage (Figures 2B and S2). Experiments with a BL2
panel of cells produced essentially similar results (data not shown).
All these results eliminate the possibility that the EBNA3s can
functionally substitute for each other in the individual deletion
viruses, and confirm that the EBNA3s are not involved in the
EBV-mediated protection of BL cells from ionomycin-induced
apoptosis.
The BHRF1 locus provides partial resistance to
ionomycin-induced apoptosis
Previous studies showed that the EBV viral BCL-2 homologue,
BHRF1, is only expressed early upon infection of resting B cells or
during lytic reactivation [16,32]. Although ionomycin treatment
does not consistently induce the viral lytic cycle in any of the panel
of BL cells studied here (for examples see Figure S3), Kelly and
colleagues have shown that BHRF1 can be expressed at a low level
during latency in ‘Wp-restricted’ BL-derived cell lines (eg. Sal-BL
and Oku-BL) and can suppress the apoptotic pathway activated by
ionomycin in BL cells when it is delivered by transfection [25]. By
western blotting with an anti-BHRF1 monoclonal antibody, we
confirmed expression of BHRF1 in Oku-BL and Sal-BL, but
detected no expression in various untreated or treated BL2, BL31
and BL41 converts or in Mutu III cells (Figure S3). However, one
could not formally exclude the possibility that BHRF1 might be
functionally active at a level that is undetectable by western
blotting extracts from these latently infected cells. Therefore, using
recombination in the B95-8 EBV-BAC, viruses were constructed
from which the BHRF1 locus was deleted (BHLOC KO) and
subsequently replaced to produce a revertant virus (BHLOC rev –
Figure 3A and B). The deletion removes not only the BHRF1
coding sequence, but also three miRNAs that have been shown to
inhibit apoptosis early after infection of primary B cells [33]. The
recombinant viruses were then used to infect EBV-negative BL31
cells and stably infected cells were selected using hygromycin and
allowed to grow out as a bulk population. Attempts to produce
BL2 lines infected with the BHLOC KO virus were unsuccessful
for reasons we don’t understand. Protein extracts from the BL31
cells established with these recombinant EBVs were analysed by
western blotting using antibodies for each of the EBV latent
proteins. It was confirmed that these cells display no consistent
changes to the levels of the EBV latent proteins – EBNA1,
EBNA2, EBNA3A, EBNA3B, EBNA3C and LMP1; however in
the two BHLOC KO lines the amount of EBNA-LP appeared
slightly elevated relative to wild type and revertant infections
(Figure 3C) – this was also reported in a recent study focusing on
the BHRF1 miRNAs [34].
In order to determine the contribution made by the BHRF1
locus to EBV-mediated protection against ionomycin-induced
apoptosis, the response to ionomycin of BL31 carrying BHLOC
KO or BHLOC rev viruses were examined. Figure 4A shows that
24 hours after exposure to ionomycin, only 25% of EBV-negative
BL31 cells remain viable, compared to .80% of BL31 cells
infected with the WT-EBV or BHLOC rev. It was apparent from
multiple experiments that BL31 cells infected with the BHLOC
KO virus showed partial resistance to ionomycin-induced
apoptosis – with about 50% of the cell population remaining
viable after 24 hours. Western blotting for PARP echoes this
result, with a substantial amount of cleaved PARP detectable in
EBV-negative BL31 cells, very little or no cleaved PARP in WT-
or BHLOC rev-infected BL31 cells, and an intermediate level of
PARP cleavage in BL31-BHLOC KO (Figure 4B). These data
indicate that the BHRF1 locus is involved in the EBV-mediated
protection of BL cells against ionomycin-induced apoptosis.
However, since the loss of the BHRF1 locus consistently resulted
in only a partial loss of protection, it is likely that another EBV
gene product(s) is also involved in the resistance to ionomycin.
EBV inhibits the induction of NOXA by ionomycin
To identify cellular factors that might be involved in the
apoptotic pathway triggered by ionomycin in BL cells and blocked
by EBV, we surveyed the changes in expression of various pro-
apoptotic proteins in BL cells exposed to ionomycin. Initially
BAD, BID, PUMA and NOXA were investigated by western
blotting (Figures 5A, S3 and S4). Although the steady-state level of
NOXA varied little between the various cell lines used here, it was
the only one of these pro-apoptotic factors that consistently
showed an increase in response to ionomycin (Figures 5A and S4).
The gene encoding NOXA is a known transcriptional target of the
tumour suppressor p53 and its expression is upregulated during
p53-mediated cell death [35]. However, western blot analysis
reproducibly showed an increase in NOXA protein levels in Mutu
I and EBV-negative BL31 cells exposed to ionomycin and since
both lines express only mutant p53 [22,36], this indicates that the
induction is not dependent on p53-mediated transactivation. In
contrast, NOXA protein levels were unaffected (or decreased) in
Mutu III cells, BL31 cells latently infected with wild type B95.8
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knockout virus (E2KO). This indicates that only a limited pattern
of EBV gene expression is necessary to block NOXA accumula-
tion. In a similar BL2 series of cells and Oku- and Sal-BL cells it
was only in the EBV-negative BL2 cells that NOXA accumulated
and apoptosis was induced in response to ionomycin. These cells
all carry wild type, transactivation competent p53 [22], but
ionomycin did not induce its stabilization (data not shown), again
consistent with NOXA induction being p53-independent. Quan-
titative reverse transcriptase PCR (qRT-PCR) analysis of RNA
from BL31 and BL2 cells established that this induction of NOXA
expression involves the modulation of NOXA mRNA and may
therefore be regulated at the level of transcription; in both the
EBV-infected converts this induction is inhibited (Figure 5B).
Together these data indicate that NOXA is consistently up-
regulated in EBV-negative and latency I BL-derived cells that
Figure 2. Deleting EBNA3A, 3B or 3C or the complete EBNA3 locus has little or no effect on ionomycin-induced apoptosis. (A) EBV-
negative BL31 cells and their converts infected with recombinant B95.8 EBV (WT), EBNA3A, -3B and -3C-knockout EBVs, or their respective revertants
were treated with 1 mg/ml ionomycin (IM) for 48 hours. (B) EBV-negative BL31 cells and their converts infected with recombinant B95.8 EBV (WT),
EBNA3 locus knockout (E3KO) or revertant (E3rev) EBVs were treated with 1 mg/ml ionomycin for 48 hours. In both (A) and (B) viable cells that exclude
trypan blue were counted after 48 hours and expressed as a percentage relative to the starting population. The mean and standard deviation from
three independent experiments are shown.
doi:10.1371/journal.pone.0028506.g002
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NOXA is independent of p53-status and can be inhibited by a
factor(s) encoded by EBV in latency state III, but does not seem to
require EBNA2, (or the LMPs) that are absent from the E2KO-
infected cells, Oku- BL and Sal-BL.
NOXA contributes to ionomycin-induced apoptosis
NOXA and its mRNA are consistently up-regulated in EBV-
negative BL cells that undergo apoptosis in response to ionomycin.
However, NOXA expression appears to be largely unaffected in
EBV-positive BL cells that are resistant to ionomycin. It was
Figure 3. Construction of an EBV-BAC recombinant virus from which BHRF1 locus has been deleted. (A) Schematic representation of the
recombinant EBVs generated with a deletion in the BHRF1 locus (BHLOC KO). Recombinant EBV-BACs harbouring a deletion of the complete BHRF1
locus were constructed. The BAC region is inserted at the site of the 10 kb deletion of B95-8 (D). Vertical arrows indicate the restriction enzyme sites
and positions (within the EBV genome sequence, Accession No V01555) between which the BHRF1 locus was deleted. This region was reinserted to
generate the revertant virus (BHLOC rev). The schematic is not drawn precisely to scale. (B) Validating BHRF1 knockout and revertant EBV-BACs. DNA
from the BHRF1 locus (BHLOC)-knockout (KO – BAC JY28+2.4) and its revertant (rev – BAC JY32+2.3) EBV-BACs as well as the wild-type EBV-BAC (WT)
were analysed by restriction digestion with AgeI (top) or EcoRI (bottom) followed by pulsed field gel electrophoresis. A mixture of l-DNA BstEII and l-
DNA mono cut mix ladders (NEB) were used as a size marker (Ladder). Bands whose sizes are changed by the deletion of the BHRF1 locus (13 kb AgeI
fragment, and the Bam W-containing EcoRI fragment lacking BHRF1 -W - DBHRF1) are indicated. The EcoRI restriction fragments that include the Bam
W repeats and the terminal repeats (TR) are also indicated. (C). Protein extracts from BL31, BL31 BHLOC KO, revertants and an LCL were separated by
SDS-PAGE and western immunoblotted with antibodies specific to the EBV proteins indicated (and the cellular protein c-tubulin as a loading control).
doi:10.1371/journal.pone.0028506.g003
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positive converts established using recombinant B95.8 (WT), BHRF1 locus-knockout (BHLOC KO) and BHRF1 locus-revertant (BHLOC rev) EBVs were
treated with 1 mg/ml ionomycin (IM) or DMSO (vehicle control). After 24 hours cell viability was determined using the CellTiter-Glo assay and
expressed relative to vehicle-treated cells. The mean and standard deviation from three independent experiments are shown. (B) Protein extracts
from cells harvested at 24-hour intervals were separated by SDS-PAGE and analysed by western immunoblotting using antibodies that detect full-
length and cleaved PARP. Ionomycin-treated cells are compared to the same cells treated with vehicle control for 48 hours (U) and c-tubulin was
used as a loading control.
doi:10.1371/journal.pone.0028506.g004
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ionomycin-induced apoptosis in sensitive BL cells. To this end,
four lentiviral vectors expressing shRNAs targeted against NOXA
mRNA were used to transduce EBV-negative BL31 and BL2 cells.
None of the lentiviruses alone achieved greater than a 40–50%
reduction in protein level (data not shown). However, transduction
of BL31 and BL2 cells with all four shNOXA lentiviruses
(shNOXAx4) achieved a substantial reduction in NOXA expres-
Figure 5. Ionomycin induces accumulation of NOXA protein and mRNA in EBV-negative and latency I BL cells, but not in EBV-
positive cells that are resistant to ionomycin-induced apoptosis. (A) Protein extracts from the cells indicated before and after exposure to
1 mg/ml ionomycin (IM) for up to 48 hours were separated by SDS-PAGE and analysed by western immunoblotting using antibodies directed against
NOXA. Throughout, c-tubulin was used as a loading control. (B) EBV inhibits the accumulation of NOXA mRNA induced by ionomycin. EBV-negative
and recombinant B95.8 (WT) EBV-converted BL31 and BL2 cells were exposed to 1 mg/ml ionomycin for up to 8 hours. Cells were harvested at 2-hour
intervals and RNA was extracted. The extracts were analysed by quantitative RT-PCR and NOXA mRNA expression was normalized to that of UBC
mRNA, which is stably expressed during ionomycin treatment/apoptosis over the time period used.
doi:10.1371/journal.pone.0028506.g005
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with the non-targeting shRNA-expressing lentiviruses to establish
lines as negative controls (Figure 6A & C).
BL31- and BL2-shNOXAx4 and shNon-target cell lines were then
exposed to ionomycin and their responses compared to those of EBV-
negative and WT EBV-converted BL31 and BL2. In both BL31 and
BL2 cell lines, cell viability after ionomycin treatment is substantially
improved as a result of NOXA knock-down, although not quite
restored to the protection offered by EBV infection (Figures 6B and D).
Similarly, PARP cleavage is reduced or prevented in the absence of
NOXA, in both BL31 and in BL2 cells (Figure S5). These observations
are consistent with either an incomplete ‘knockdown’ of NOXA, or
with the possibility that NOXA represents a partial component of the
apoptotic stimulus caused by ionomycin, but either way, confirm that
NOXA makes a major contribution to the apoptosis induced in these
cells by ionomycin.
Figure 6. shRNA-mediated knockdown of NOXA protects against ionomycin-mediated apoptosis. BL31 cells were transduced with
multiple (shNOXAx4) lentiviral vectors carrying shRNA directed against NOXA mRNA, or with a non-target shRNA control (shNon-target) lentivirus. (A)
Western immunolotting shows the reduction in basal NOXA expression due to the shRNAs; c-tubulin was used as a loading control. (B) BL31-
shNOXAx4 and BL31-shNon-target, EBV-negative BL31 and its B95.8 (WT) EBV convert were exposed to DMSO (vehicle control), or 0.5 or 1 mg/ml
ionomycin (IM) for 24 hours. Cell viability was determined by CellTiter-Glo assay and expressed as a percentage of vehicle-treated controls. The mean
and standard deviation of three independent experiments is shown. (C) BL2 cell lines transduced with lentiviruses as (A) above, and immunoblotted
to show levels of NOXA depletion. (D) BL2 cell lines treated with ionomycin and assayed as described in (B).
doi:10.1371/journal.pone.0028506.g006
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the inhibition of NOXA induction
Since BL31 cells latently infected with an EBNA3 knockout
virus (E3KO) are resistant to ionomycin, it was predictable that
EBV carrying this deletion would still block NOXA accumulation.
This is formally shown in Figure 7A. However, more surprising
was the observation that virus with the BHRF1 locus deletion –
despite providing reduced resistance to ionomycin treatment – also
suppressed NOXA accumulation as effectively as revertant and
WT B95.8 EBVs (Figure 7B).
Responses of BL-derived cells to staurosporine and
etoposide confirm two distinct pathways
Staurosporine is a broad-spectrum protein kinase inhibitor, is
widely used as an inducer of apoptosis in a variety of cell types, but
is chemically unrelated to ionomycin [37]. Etoposide is a DNA
topoisomerase II inhibitor that can induce apoptosis through DNA
damage-induced p53 activation [38].
Similar experiments to those described above were performed
to assess the responses of BL-derived cells to staurosporine and
etoposide in order to establish whether they could be categorised
with either ionomycin or the genotoxins. Initially Mutu I and
Mutu III were compared. Although both staurosporine and
etoposide induced apoptosis in Mutu I, latency-III EBV gene
expression (in Mutu III) substantially enhanced survival after both
treatments (Figure 8A & B). Staurosporine induced NOXA in
sensitive Mutu I cells, but in contrast, etoposide had no effect on
NOXA levels and must therefore activate a separate pathway
(Figure 8C). When the BHLOCKO infected cells were tested, they
exhibited partial resistance to both staurosporine and etoposide,
but as expected, the BHLOC KO virus still blocked NOXA
accumulation (Figures 9A and S6). It seems that the BHRF1 locus
enhances survival irrespective of the type of trigger, but acts
independently of NOXA.
When BL31 cells infected with the EBNA3 locus knockout
(E3KO) series were analysed in similar assays, the deletion viruses
showed similar levels of protection to B95.8-BAC (WT) EBV in
response to staurosporine. In contrast when the cells were treated
with etoposide, only 10–20% of the E3KO-infected cells survived,
but NOXA was not induced (Figure 9B and S7). These
observations suggest that staurosporine induces apoptosis in BL
cells by activating the same or a similar pathway to that activated
by ionomycin whereas etoposide works, like cisplatin, via a second
distinct pathway associated with DNA damage.
Discussion
Previous work in our laboratory showed that the resistance
conferred by EBV against cell death induced by agents that cause
damage to DNA, including the mitotic spindle poison nocodazole
and the DNA cross-linking agent cisplatin, is dependent on the co-
expression of EBNA3A and EBNA3C [22]. Here we have
expanded this group to include etoposide (see below). Protection
correlates with the down-regulation of the BH3-only pro-apoptotic
protein BIM by the combined action of EBNA3A and EBNA3C,
but is only apparent in the absence of a functional p53. When BIM
is not expressed, but p53 is functional (as for instance in BL2 cells),
latent EBV does not appear to provide any survival advantage
against apoptosis induced by these genotoxic drugs. These findings
appeared to be inconsistent with the observations made by Kelly
and colleagues that EBV protects both BL2 cells (that carry WT
p53, but are BIM-negative) and BL31 cells (that carry mutant p53,
but are BIM-positive) to a similar extent when apoptosis was
induced by the calcium ionophore, ionomycin [20,25]. We
hypothesised that ionomycin must activate a distinct apoptotic
pathway in BL cells that is both independent of p53 status and not
associated with BIM. We confirm here that latent EBV protects
cells from ionomycin and also the apparently unrelated drug
staurosporine via a similar pathway and show that EBV blocks the
accumulation of the pro-apoptotic protein NOXA that is induced
by both of these agents.
The data from BL41 cells infected with P3HR1 virus and BL2
cells infected with a recombinant virus that also fail to express
EBNA2 (E2KO) were consistent with a restricted pattern of viral
gene expression – EBNA1, EBNA3A, EBNA3B, EBNA3C,
Figure 7. Neither the EBNA3 nor the BHRF1 loci are necessary to
block the induction of NOXA. (A) A comparison of NOXA induction
in EBNA3KO and EBNA3 revertant BL31 cells after treatment with
ionomycin (IM) and analysis by western immunoblotting. (B) Similar
analysis of BHLOC KO BL31 lines and a revertant line. Induction of NOXA
by ionomycin in BL31 is shown for comparison. Throughout c-tubulin
was used as a loading control.
doi:10.1371/journal.pone.0028506.g007
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in B95.8 being sufficient for protection from ionomycin. We
obtained similar results with Oku-BL and Sal-BL that carry a virus
with a similar genomic deletion to P3HR1. If EBV gene
expression was restricted further, as in Mutu I cells (EBNA1,
EBERs and BARTs only) there was no protection. Analyses
utilizing recombinant EBVs carrying specific gene deletions of
EBNA3A, EBNA3B, EBNA3C or the whole EBNA3 locus showed
that none of these genes is necessary for the survival phenotype
and that there is no functional redundancy – that is, one EBNA3
cannot substitute for either of the others.
It was recently shown that BHRF1 might not be a strictly ‘lytic’
product and that the genomic locus from which it derives is also
the source of three potentially anti-apoptotic miRNAs [16,25,33].
We therefore constructed a recombinant EBV from which the
complete BHRF1 locus was deleted to formally test whether these
potentially anti-apoptotic factors are required for protection of
latently infected cells against ionomycin (and staurosporine).
Figure 8. Comparison of staurosporine- and etoposide-induced apoptosis in Mutu BL cells. Mutu I and Mutu III cells were exposed to
0.25 mM staurosporine (STS) or 800 ng/ml etoposide (ETP) for 24 hours or 72 hours respectively. (A) Cell viability was determined using the CellTiter-
Glo assay and expressed as a percentage of DMSO vehicle-treated cells. The mean and standard deviation of three independent experiments is
shown. Protein was extracted from cells harvested at the start of treatment and the times indicated. Western immunoblotting was performed using
antibodies that detect PARP (B) or NOXA (C). U indicates vehicle-treated control cells after 24 or 72 hours, and c-tubulin was used as a loading
control.
doi:10.1371/journal.pone.0028506.g008
EBV Blocks NOXA Induction
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28506Deletion of the BHRF1 locus partially sensitized latently infected
BL31 cells to these drug treatments, indicating that the locus must
be involved in mediating resistance. However at this stage we
cannot say whether this is due to the action of BHRF1 protein (a
BCL-2 homologue) or the BHRF1 miRNAs or both. Furthermore,
since the reduction in survival is only partial, this implies that
another EBV factor(s) contributes to the resistance phenotype by
an as yet unidentified mechanism.
BH3-only proteins are critical mediators of the intrinsic
apoptotic pathway (reviewed in [39]). Therefore, in order to
identify cellular factors that might be associated with the apoptotic
pathway activated by ionomycin (and staurosporine), the expres-
sion of pro-apoptotic BH3-only members of the BCL-2 family –
BAD, BID, NOXA and PUMA – was investigated. Of these
NOXA was the only protein consistently induced in EBV-negative
and latency I BL cells that were sensitive to treatment with both
ionomycin and staurosporine. In contrast, up-regulation of NOXA
did not occur in any EBV-positive BL cells exhibiting resistance to
the drugs. These data suggested that apoptosis triggered by
ionomycin and staurosporine involves the induction of NOXA
expression and that EBV rescues BL cells from apoptosis, at least
in part, by inhibiting the accumulation of NOXA. ShRNA-
mediated knock-down of NOXA expression was able to
substantially enhance the survival of EBV-negative BL31 and
Figure 9. The BHRF1 locus makes a significant contribution to resistance against both staurosporine and etoposide, but the EBNA3s
only protect against genotoxin-induced damage. (A) EBV-negative BL31, its recombinant B95.8 (WT) EBV convert and BL31 cell lines
established with recombinant BHRF1 locus-knockout (BHLOC KO) and revertant (BHLOC rev) EBVs were treated with 0.25 mM staurosporine (STS, left
panel) or 800 ng/ml etoposide (ETP, right panel) for up to 24 hours. Cell viability was determined after 24 hours using the CellTiter-Glo assay and
expressed as a percentage of DMSO vehicle-treated cells. (B) Experiments and analysis described in (A) performed on BL31 converts made with
EBNA3 locus knockouts (E3KO) and revertant virus.
doi:10.1371/journal.pone.0028506.g009
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induced apoptosis is at least partly mediated by NOXA and that
inhibiting its expression can promote B cell survival. The presence
of shRNA against NOXA did not prevent its induction by
ionomycin, but since NOXA was induced from a lower baseline
level, the improved survival manifested as delayed apoptosis
(apparent at 24 hours post treatment) rather than as complete
resistance – if the cells were left long enough they died. We assume
the rate at which new RNA was synthesised outstripped the
capacity of the shRNA to inactivate NOXA message. Despite
these technical drawbacks inherent in shRNA experiments, the
results were highly reproducible and consistent in two different cell
backgrounds.
It was more surprising to see that NOXA levels did not increase
in EBV-positive BL cells lacking the BHRF1 locus, since they are
partially sensitive to ionomycin and staurosporine treatment. This
suggests that these drugs trigger an additional pro-apoptotic
mechanism in addition to NOXA induction, which is blocked by
the active component of the BHRF1 locus – this could be BHRF1,
expressed at a low level as hypothesised by Kelly et al, mimicking
BCL-2 and neutralizing multiple pro-apoptotic factors.
The increase in NOXA protein after drug-treatment was
mirrored by an increase in NOXA mRNA, suggesting that the
regulation is at the level of RNA turnover or transcription. Since
wild type p53 is absent from BL41, BL31 and Mutu I cells the
induction of NOXA expression by ionomycin does not involve
p53-mediated activation of NOXA transcription. Consistent with
this, ionomycin does not induce the stabilization and accumulation
of wild type p53 in BL2 cells (data not shown). However, it is
currently unclear by what signalling pathway ionomycin (or
staurosporine) induces the accumulation of NOXA. Furthermore,
using the various mutants of EBV described above, we were
unable to identify the viral gene or gene product(s) that is
responsible for the block in NOXA accumulation. None of the
latency-associated proteins, the EBERs, BHRF1, the BHRF1
miRNAs or most of the BART miRNAs, appear to be necessary to
block the ionomycin-induced increase in NOXA. Of the currently
recognised latency-associated gene products only the BART
miRNAs that are not missing from the B95.8 genome (miR-
BARTs 1, 2, 3, 4 and 15 [40], or the W1W2 repeat region of
EBNA-LP [15] remain as candidates for this regulation. However,
at this stage we cannot formally exclude a contribution by
products from other regions of the EBV genome not presently
associated with latency.
Finally, etoposide – a DNA topoisomerase II inhibitor and
therefore another drug that can cause damage to DNA – also
triggered apoptosis that was blocked by latency III EBV gene
expression in Mutu and BL31 cells. Apoptosis did not involve the
induction of NOXA, but resistance required expression of
EBNA3A and EBNA3C, in this respect etoposide has a similar
mode of action to cisplatin and nocodazole. These data are
consistent with the hypothesis of two distinct pathways and suggest
that EBNAs 3A and 3C might play a specific role in the DNA
damage response, in addition to the regulation of apoptosis per se.
Materials and Methods
Cell culture
Burkitt’s lymphoma-derived cell lines: BL41, BL41/B95.8,
BL41/P3HR1, Oku-BL, Sal-BL, BL2, BL31, Mutu I-clone 179
and Mutu III [described in [21,22]; lymphoblastoid cell lines:
LCL-BF and LCL-CH (described in [24,30]) and HEK293 cells
[31] were all cultured in RPMI 1640 medium containing L-
glutamine (Invitrogen, UK) supplemented with 10% fetal calf
serum and penicillin-streptomycin at 37uC in a humidified
incubator with 10% CO2. BL2 and BL31 cell lines were
additionally supplemented with 1 mM sodium pyruvate (Sigma,
UK) and 50 mM a-thioglycerol (Sigma). Hygromycin B (Roche,
UK) was added at a concentration of 100 mg/ml to all BL cell lines
containing recombinant hygromycin-resistant EBV. BL2 cells
infected with a recombinant EBNA2-knockout virus (BL2+E2KO)
[20]. For routine passage, cells were split 1:3 every 2 or 3 days. For
experiments, all cells were re-suspended in fresh medium at a
density of 3610
5 cells/ml 24 hours prior to manipulation.
Generation and use of recombinant viruses
BL31 and BL2 cell lines carrying recombinant EBNA3 mutants
and their revertants were described previously [22,31]. EBV
containing a deletion of the BHRF1 locus was generated using
recA-mediated recombination. Briefly, the region of the EBV
genome containing the BHRF1 locus was sub-cloned, and digested
with SmaI/PstI, treated with Klenow and re-ligated, to remove
the fragment corresponding to positions 41399–43125 of the EBV
genome (Accession number V01555). Approximately 500 bp on
each flank of this deletion enabled homologous recombination
with the B95-8 EBV-BAC genome [41], using a markerless
insertion technique [42], to generate BHLOC KO EBV.
Revertants of this (BHLOC rev) were generated using the same
region of EBV lacking the deletion, which was reintroduced into
the EBV-BAC genome to revert the mutant to the wild-type
sequence. Mutant and revertant viruses were tested for the
presence/absence of the desired mutation, and screened for
undesired deletions/alterations by restriction digestion and pulsed-
field gel electrophoresis. Recombinant EBV-BAC was transfected
into HEK-293 cells that were selected with hygromycin, cloned,
screened and used to generate virus as described elsewhere [43].
These recombinant viruses were used to infect BL31 and BL2 cells
as described previously [22,31].
Induction of cell death and measurement of cell viability
Ionomycin (Sigma), staurosporine (Sigma) and etoposide
(Calbiochem) were reconstituted in DMSO to form stock
solutions. Ionomycin was added to the cell medium to give a final
concentration of 1 mg/ml unless otherwise stated. Staurosporine
was used at a final concentration of 0.25 mM and etoposide was
used at a final concentration of either 500 or 800 ng/ml. Viable
cell counts were performed using a hemocytometer and based on
the exclusion of trypan blue dye, or in some experiments, cell
viability was measured using the CellTiter-Glo
TM Luminescent
Cell Viability Assay (Promega) according to the manufacturer’s
instructions. In this assay ATP activity is used as a measure of
viable cells.
Western blot analysis
This was performed essentially as previously described [44].
Briefly, protein extracted using RIPA buffer were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to Protran nitrocellulose membranes
(Schleicher & Schuell Bioscience). Membranes were blocked with
5% skimmed-milk in phosphate buffered saline (PBS) containing
0.05% Tween 20, probed with appropriate primary and HRP-
conjugated secondary or tertiary antibodies. An ECL kit
(Amersham Biosciences) was used for visualization. Primary
antibodies were used according to the manufacturer’s instructions:
rabbit polyclonal anti-poly(ADP-ribose) polymerase or PARP
(Roche), mouse monoclonal anti-c-tubulin (GTU-88; Sigma),
mouse monoclonal anti-NOXA (114C307; Calbiochem), rabbit
polyclonal anti-BIM (Stressgen), rabbit polyclonal anti-PUMA
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Laboratories), rabbit polyclonal anti-BAD (Cell Signaling), mouse
monoclonal anti-BHRF1 (5B11; Chemicon), sheep polyclonal
anti-EBNA3A (Exalpha), sheep polyclonal anti-EBNA3B (Exal-
pha), mouse monoclonal anti-EBNA3C (A-10), mouse monoclonal
anti-LMP1 (CS1–4; DAKO), mouse monoclonal anti-EBNA2
(PE2; DAKO), mouse monoclonal anti-EBNA-LP (JF186; [45])
and human serum that recognizes EBNA1 (a gift from Paul
Farrell). Human serum EE was from a patient with chronic
infectious mononucleosis and has a very high titre of antibodies
recognizing EBV early lytic antigens [46]. The human sera were
used at a concentration of 1/10,000.
Lentiviral-mediated shRNA
Lentiviruses carrying shRNA directed against NOXA [MIS-
SIONH shRNA, Sigma (TRCN0000: 150555,151311,153637,
155570)] were used to transduce EBV-negative BL31 and BL2
cells at an MOI of 10. A non-targeting shRNA lentiviral vector
was used as a negative control. Transduced cells were selected in
puromycin (1 mg/ml) and the amount of NOXA depletion
achieved by shRNAs was assessed by western blotting and real-
time quantitative RT-PCR analyses (data not shown).
Real-time quantitative RT-PCR
Total cellular RNA was extracted using RNeasy Mini kits
(Qiagen) as per the manufacturer’s instructions. Real-time
quantitative RT-PCR was performed in triplicate on 0.1 mg
RNA using the QuantiFast SYBR Green RT–PCR kit (Qiagen)
and ABI 7900HT Fast Real-Time PCR system (Applied
Biosystems). NOXA mRNA was quantified relative to ubiquitin
C (UBC) mRNA using the following primer sets: NOXA
(GAACGCGCCAGTGAACCCAA and CTTTGTCTCCAA-
TCCTCCGG) and UBC (ATTTGGGTCGCGGTTCTTG and
TGCCTTGACATTCTCGATGGT). The cycling conditions
used were 95uC for 10 s followed by 60uC for 30 s.
Supporting Information
Figure S1 Latent EBV inhibits ionomycin-induced ap-
optosis in a variety of cell backgrounds. BL41 and its EBV-
positive counterparts, BL41/B95.8 and BL41/P3HR1, two Wp-
restricted BL Oku-BL and Sal-BL, BL2 and its EBV-positive
convert established using a recombinant EBNA2-knockout (E2KO)
virus, latency I and latency III Mutu, and two lymphoblastoid cell
lines (LCLs) were all exposed to 1 mg/ml ionomycin (IM) for up to
48 hours. Protein was extracted from cells harvested at the start of
the treatment and the times indicated. Protein extracts were
separated by SDS-PAGE and analysed by western blotting using
antibodies which detect full-length and cleaved poly(ADP-ribose)
polymerase or PARP. U indicates untreated negative control cells
and C indicates treated cells (BL2 plus IM) after 48 hours used as a
positive control. Throughout, c-tubulin was used as a loading
control.
(TIF)
Figure S2 The EBNA3 locus is not involved in the EBV-
mediated protection against ionomycin-induced apop-
tosis. The EBV-negative BL31 cell line, its recombinant B95.8-
BAC EBV convert, BL31 cell lines established using individual
EBNA3A-, 3B- and 3C-knockout viruses and their respective
revertants, as well as BL31 cells lines converted with recombinant
EBNA3 locus-knockout (E3KO) and revertant (E3rev) EBVs were
all treated with 1 mg/ml ionomycin (IM) for up to 48 hours.
Protein was extracted from cells harvested at the start of the
treatment and at the times indicated. Protein extracts were
separated by SDS-PAGE and analysed by western blotting using
antibodies that detect full-length and cleaved PARP. U indicates
untreated control cells after 48 hours. Throughout, c-tubulin was
used as a loading control.
(TIF)
Figure S3 Rescue from apoptosis induced by ionomycin
is not dependent on EBV lytic gene expression and Wp-
restricted BL lines express BHRF1. Various EBV-positive
BL cells were treated with 1 mg/ml ionomycin (IM) for 48 hours
and harvested at the times indicated. Protein extracts from treated
cells were separated by SDS-PAGE and analysed by western
blotting using (A) the human serum EE which detects lytic antigens
and (B) and (C) monoclonal antibodies against BHRF1 and
BZLF1. Extracts from Akata cells [47] left untreated (2) or treated
with anti-Ig [+ or (+)] to stimulate the expression of EBV lytic
proteins were included to show lytic gene expression. BZLF1 was
used as a control for lytic activation and c-tubulin was used a
loading control.
(TIF)
Figure S4 Ionomycin does not consistently induce
expression of BAD, BID or PUMA. Protein extracts from
representative BL-derived cells treated with 1 mg/ml ionomycin
(IM) for up to 48 hours were analysed by western blotting using
antibodies directed against the pro-apoptotic BH3-only factors
PUMA, BAD and BID. Throughout, c-tubulin was used as a
loading control.
(TIF)
Figure S5 shRNA-mediated knockdown of NOXA in-
creases resistance to ionomycin-induced apoptosis.
BL31 and BL2 cells established using lentiviral vectors expressing
shRNA targeted against NOXA were exposed to ionomycin (IM)
at the concentrations indicated for up to 48 hours. BL cells
established using lentiviruses expressing a non-targeting shRNA
were included as controls. Protein was extracted from cells
harvested at the start of the treatment and the times indicated.
Western blotting was performed for evidence of PARP cleavage. U
indicates vehicle-treated control cells after 48 hours. Throughout,
c-tubulin was used as a loading control.
(TIF)
Figure S6 The BHRF1 locus contributes to the EBV-
mediated protection against apoptosis induced by both
staurosporine and etoposide. EBV-negative BL31, its
recombinant B95.8-BAC EBV convert and BL31 cell lines
established with recombinant BHRF1 locus-knockout (BHLOC
KO) and revertant (BHLOC rev) EBVs were treated with
0.25 mM staurosporine (STS) for up to 24 hours or 500 ng/ml
etoposide (ETP) for up to 48 hours. Protein was extracted from
cells harvested at the start of the treatment and the time points
indicated. Western blotting was performed using antibodies
directed against PARP (top and bottom panels) and directed
against NOXA (middle panel). U indicates vehicle-treated control
cells after 24 or 48 hours. Throughout, c-tubulin was used as a
loading control.
(TIF)
Figure S7 The EBNA3 locus protects against etoposide
(genotoxin)-, but not staurosporine-induced apoptosis.
Similar experiments and analysis to (S6) were performed using
BL31 cell lines established using recombinant EBNA3 locus-
knockout (E3KO) and revertant (E3rev) EBVs.
(TIF)
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